HemaCord (New York Blood Center)


Welcome to the PulseAid listing for the HemaCord drug offered from New York Blood Center. This Allogeneic Cord Blood Hematopoietic Progenitor Cell Therapy [EPC],Hematopoietic Stem Cells [Chemical/Ingredient],Cells, Allogeneic [Chemical/Ingredient] pharmaceutical is classified as a CELLULAR THERAPY. Below, you can view the details for this drug, such as its dosage form, route of delivery, start market/end market dates, and more. We have also randomly listed additional pharmaceuticals used in the same CELLULAR THERAPY drug type category.

LABELER NAME / MANUFACTURER: New York Blood Center
NON-PROPRIETARY NAME: HUMAN CORD BLOOD HEMATOPOIETIC PROGENITOR CELL
SUBSTANCE NAME: HUMAN CORD BLOOD HEMATOPOIETIC PROGENITOR CELL
TYPE: CELLULAR THERAPY
PHARMA CLASS: Allogeneic Cord Blood Hematopoietic Progenitor Cell Therapy [EPC],Hematopoietic Stem Cells [Chemical/Ingredient],Cells, Allogeneic [Chemical/Ingredient]
ROUTE: INTRAVENOUS
DOSAGE FORM: INJECTION
MARKETING CATEGORY NAME: BLA
START MARKETING DATE: 2011-11-10
END MARKETING DATE: 0000-00-00


HemaCord CELLULAR THERAPY Details:

Item DescriptionHemaCord from New York Blood Center
LABELER NAME: New York Blood Center
DEA SCHEDULE:
ACTIVE STRENGTH: 500000000(1/25mL)
START MARKETING DATE: 2011-11-10
END MARKETING DATE: 0000-00-00
PRODUCT ID: 76489-001_3423e193-0e4c-4c64-9e56-cd6ff57ac316
PRODUCT NDC: 76489-001
APPLICATION NUMBER: BLA125397

Other HUMAN CORD BLOOD HEMATOPOIETIC PROGENITOR CELL Pharmaceutical Manufacturers / Labelers:

Manufacturer / LabelerProprietary Name
New York Blood CenterHemaCord